Overall, these data indicate that CFTR modulators have potent innate anti-inflammatory properties, indicating IL-18 and IL-1b are potential reliable biomarkers for drug effectiveness at downregulating inflammation in CF [35]. This evidence concerns the gene IL18 and cystic fibrosis.